A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis

This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexat e 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and th e target sample size is <500 individuals.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Drug: tocilizumab [RoActemra/Actemra]; Drug: methotrexate

• Study Type: Interventional
• Enrollment (Actual): 418
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1280AEB
  • Buenos Aires, Argentina, C1426AAL
  • Buenos Aires, Argentina, C1425ASQ
  • Córdoba, Argentina, X5000FAL
  • San Miguel, Argentina, T4000AXL
  • San Miguel De Tucuman, Argentina, T4000IFP
• Brazil
  • BA
    • Salvador, BA, Brazil, 40050-410
  • CE
    • Fortaleza, CE, Brazil, 60170001
  • DF
    • Brasilia, DF, Brazil, 70840-901
  • ES
    • Vitoria, ES, Brazil, 29043-910
  • MG
    • Belo Horizonte, MG, Brazil, 30150-221
    • Juiz de Fora, MG, Brazil, 36010-570
  • PE
    • Recife, PE, Brazil, 50000-000
  • PR
    • Curtiba, PR, Brazil, 80030-110
  • RJ
    • Rio de Janeiro, RJ, Brazil, 20551-030
  • RS
    • Caxias do Sul, RS, Brazil, 95070-560
    • Porto Alegre, RS, Brazil, 90035-003
    • Porto Alegre, RS, Brazil, 90610-000
  • SC
    • Florianopolis, SC, Brazil, 88040-970
  • SP
    • Botucatu, SP, Brazil, 18600-400
    • Campinas, SP, Brazil, 13059-900
    • Campinas, SP, Brazil, 13083-888
    • Ribeirao Preto, SP, Brazil, 14048-900
    • Santo Andre, SP, Brazil, 09060-650
    • Sao Jose do Rio Preto, SP, Brazil, 15090-000
    • Sao Paulo, SP, Brazil, 04266-010
    • Sao Paulo, SP, Brazil, 04039-004
    • Sao Paulo, SP, Brazil, 04027-000
• Chile
  • Concepcion, Chile, 1436
  • Santiago, Chile, 7500000
  • Santiago, Chile, 8320000
  • Santiago, Chile, 352
  • Santiago, Chile, 7550000
  • Santiago, Chile, 8380000
  • Santiago, Chile, 8860000
  • Temuco, Chile, 4780000
• Colombia
  • Barranquilla, Colombia
  • Bogota, Colombia
  • Bogota, Colombia, 49 00
  • Bogotá, Colombia
  • Bucaramanga, Colombia
  • Cali, Colombia
  • Chia-Cundinamarca, Colombia
  • Medellin, Colombia
  • Medellín, Colombia
• Costa Rica
  • Cartago, Costa Rica
  • Heredia, Costa Rica, 00
  • San Jose, Costa Rica, 10103
  • San José, Costa Rica
• Ecuador
  • Cuenca, Ecuador
  • Guayaquil, Ecuador
  • Quito, Ecuador
  • Quito, Ecuador, EC170517
• Mexico
  • Chihuahua, Mexico, 31238
  • Guadalajara, Mexico, 44650
  • Mexico City, Mexico, 14140
  • Mexico City, Mexico, 03900
  • Mexico City, Mexico, 11850
  • Miexico City, Mexico, 06700
  • Queretaro, Mexico, 76000
  • San Luis Potosi, Mexico, 78240
• Peru
  • Arequipa, Peru, 04001
  • Jesus Maria, Peru
  • Lima, Peru, LIMA 14
  • San Isidro, Peru, Lima 27
• Uruguay
  • Montevideo, Uruguay, 11000
• Venezuela
  • Barquisimeto, Venezuela, 3005
  • Caracas, Venezuela, 1010
  • Caracas, Venezuela, 1040
  • Maracaibo, Venezuela, 4001

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• patients >=18 years with moderate to severe active RA for at least 6 months;
• swollen joint count >=6 (66 joint count) and tender joint count >=8 (68 joint count) at screening;
• inadequate response to stable dose of MTX;
• patients of reproductive potential must be using a reliable means of contraception.

Exclusion Criteria:

• rheumatic autoimmune disease other than RA;
• patients with functional class IV RA;
• diagnosis of juvenile idiopathic or rheumatoid arthritis before age 16 or a history of current inflammatory joint disease other than RA;
• prior treatment failure with anti-tumor necrosis factor agent;
• pregnant or breastfeeding women.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1	Drug: tocilizumab [RoActemra/Actemra]; 8mg/kg iv, every 4 weeks; Drug: methotrexate; 10-25mg oral or parenteral weekly.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24	ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments: Participant's global assessment of pain by Visual Analog Scale (VAS); Participant's global assessment of disease activity (VAS); Investigator/Physician's global assessment of disease activity (VAS); Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI); Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With ACR20 and ACR70 Response at Week 24	ACR20 and ACR70 are defined as 20 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: Participant's global assessment of pain by VAS; Participant's global assessment of disease activity (VAS); Investigator/Physician's global assessment of disease activity (VAS); Participant's assessment of disability measured by HAQ-DI; Acute phase reactant (ESR or CRP)	Week 24
Time to Onset of ACR20, ACR50, and ACR70	ACR20, ACR50 and ACR70 are defined as 20, 50 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: Participant's global assessment of pain by VAS; Participant's global assessment of disease activity (VAS); Investigator/Physician's global assessment of disease activity (VAS); Participant's assessment of disability measured by HAQ-DI; Acute phase reactant (ESR or CRP)	Baseline and Week 24
Change From Baseline in Hemoglobin at Week 24		Baseline and Week 24
SJC and TJC at Baseline and Week 24	The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).	Baseline and Week 24
Percent Change From Baseline in SJC and TJC at Week 24	The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).	Baseline and Week 24
Pain as Assessed by the Participant at Baseline and Week 24	The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.	Baseline and Week 24
Percent Change From Baseline in Pain as Assessed by the Participant at Week 24	The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.	Baseline and Week 24
Participant's Global Assessment of Disease Activity at Baseline and Week 24	The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).	Baseline and Week 24
Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24	The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).	Baseline and Week 24
Physician's Global Assessment of Disease Activity at Baseline and Week 24	The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).	Baseline and Week 24
Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24	The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).	Baseline and Week 24
HAQ-DI at Baseline and Week 24	HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 =without difficulties; 1= with some difficulties; 2=with great difficulties; and 3= unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).	Baseline and Week 24
Percent Change From Baseline in HAQ-DI at Week 24	HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).	Baseline and Week 24
Area Under The Curve (AUC) of the ACR(n)	ACR-n was defined as the lowest of 3 values (the percent change in the swollen joint count, the percent change in the tender joint count, and the median of the other 5 measures in the ACR core data set which included Participant's global assessment of pain (VAS), Participant's global assessment of disease activity (VAS), Investigator/Physician's global assessment of disease activity (VAS), Participant's assessment of disability measured by the HAQ-DI Acute phase reactant levels - ESR or CRP). Therefore, a percentage value was assigned to each participant at each timepoint. AUC was calculated for each participant from baseline to Week 112. Mean and standard deviation values are are provided in percent*years.	Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving ACR20 Response	ACR20 is defined as 20% improvement in: a) SJC and TJC and b) Three of the following 5 assessments: Participant's global assessment of pain (VAS); Participant's global assessment of disease activity (VAS); Investigator/Physician's global assessment of disease activity (VAS); Participant's assessment of disability measured by the HAQ-DI; Acute phase reactant levels - ESR or CRP	Week 2
Odds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models	The probability of ACR positive response was determined using the GEE.	Weeks 2, 4, 8, 12, 16, 20, 24
Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24	DAS28 calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) >3.2 to 5.1 = moderate to high disease activity.	Baseline and Week 24
Percentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24	DAS28- based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline >1.2 with DAS28 < 3.2; moderate response: change from baseline >1.2 with DAS28 >3.2 to <5.1 or change from baseline >0.6 to <1.2 with DAS28 <5.1; No response: change from baseline < 0.6 or change from baseline >0.6 and <1.2 with DAS28 >5.1.	Week 24
AUC of DAS28	The AUC was computed using the trapezoidal rule, considering baseline value as 0, through NCSS software. For each participant, AUC for DAS28 units was calculated. Each individual AUC DAS28 value was divided by 52 to have the conversion of AUC DAS28 in unit weeks to AUC DAS28 in unit years, as 1 week is approximately 1/52 years. The set of individual AUC DAS28 was computed as summary statistics.	Weeks 2, 4, 8, 12, 16, 20 and 24
Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24	FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.	Week 24
Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24	DAS28 calculated from the SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) >3.2 to 5.1 = moderate to high disease activity and DAS28<2.6 = remission	Week 24
Quality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24	SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. Total of 3 variables were analyzed (2 composite subscales and vitality score). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).	Week 24
Mean Change in Rheumatoid Factor (RF) at Week 24 in Participants With Positive RF		Baseline and Week 24

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start: February 1, 2009
• Primary Completion (Actual): October 1, 2012
• Study Completion (Actual): October 1, 2012

Study Registration Dates

• First Submitted: September 17, 2008
• First Submitted That Met QC Criteria: September 17, 2008
• First Posted (Estimate): September 18, 2008

Study Record Updates

• Last Update Posted (Estimate): May 15, 2015
• Last Update Submitted That Met QC Criteria: May 13, 2015
• Last Verified: May 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents; Reproductive Control Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Methotrexate
• Other Study ID Numbers: ML21530